Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevanolol
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bevanolol is a cardioselective beta-1 adrenergic receptor antagonist with additional alpha-1 adrenergic blocking activity. It is primarily indicated for the management of hypertension and angina pectoris. By blocking beta-1 receptors in the heart, it reduces heart rate and myocardial contractility, while its alpha-1 blocking properties contribute to peripheral vasodilation, collectively lowering blood pressure. Bevanolol has been noted in clinical research for its potential impact on sexual function in hypertensive patients compared to other beta-blockers. It was originally developed by Warner-Lambert and is marketed in several countries, including China and Japan.
- Brand names
- BeifanluoerBentos
- Other names
- bevanolol hydrochloride
02
Targets
ADRA1A (α1A)ADRB1 (β1)ADRB2 (β2)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on bevanolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevanolol.